Key Points The company signed a licensing agreement with South Korea's Kawngdong Pharmaceutical. This is one of the top pharma companies in the prosperous Asian country. 10 stocks we like better than Ocugen › On Monday, investors clearly saw excellent value in the stock of Ocugen (NASDAQ: OCGN), a biotech that concentrates on treatments for eye disorders. They traded the company's shares up by more than 12%, on the back of a fresh licensing agreement signed with a peer in Asia. That 12% absolutely ...